Media

Media

GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company has one FDA-approved therapy for sickle cell disease and one investigational therapy in development for the disease.

Recent News

DateTitle
12/04/19GBT Announces New Employment Inducement Grants
11/26/19GBT Announces Participation at Upcoming Investor Conferences in December
11/25/19FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
11/07/19GBT Reports Recent Business Progress and Third Quarter 2019 Financial Results

More »

Media Resources


Media Contact

Steven Immergut (media)
GBT
650-410-3258
media@gbt.com